Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Vericel Corp

VCEL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Mid Cap Analyst: BUY

Last Close

$44.26

▲ +1.54%

Market Cap $2.27B · Vol 197.24K

Key Metrics

P/E Ratio

105.97

FWD: 58.48

Market Cap

$2.27B

Mid Cap

Div Yield

N/A

EPS Growth

+71.48%

YoY

RSI (14)

36.41

Momentum

Beta

1.06

vs Market

52W High

$49.32

10.26% below

52W Low

$29.00

52.62% above

Volume

197.24K

Avg 189.44K

P/B

5.14

Price-to-book

ROE

N/A

Return on equity

Free Float

98.80%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Vericel Corp (VCEL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VCEL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.20%

-5.10%

+26.93%

+18.31%

YTD

+22.91%

+21.86%

+35.64%

-10.55%

Financials & Valuation

TTM · Annual

Total Revenue	$276.26M
Net Income	$16.52M
Revenue Growth (YoY)	+22.48%
Gross Margin	74.42%
Operating Margin	4.00%
Net Profit Margin	5.98%
ROE	N/A
ROA · ROIC	3.77% · 5.27%

P/E Ratio	105.97
Forward P/E (FY1)	58.48
PEG Ratio	1.96
P/S	6.80
P/B	5.14
P/FCF	75.88
EPS Growth	+71.48%
Outstanding Shares	51.21M

Technical Indicators

50-Day SMA	$44.05
200-Day SMA	$37.94
RSI (14)	36.41
Beta	1.06
52-Week High	$49.32
52-Week Low	$29.00

Volume Today	197.24K
Avg Daily Volume (30D)	189.44K
Relative Volume	1.04x
Volatility (10D)	21.21
Volatility (30D)	28.91
Free Float	98.80%

Analyst Consensus

BUY

Current Price $44.26

Mean Target $60.57

52W Low$29.00 52W High$49.32

Current

Target

$29.00 $49.32

Current Analyst target

+36.85% upside potential · 8 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001S6X9M3

ISINUS92346J1088

CountryUnited States of America

Sub-IndustryBiopharmaceuticals

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

REGN Regeneron Pharmaceuticals Inc +0.53% CSL.AX CSL Ltd +17.25% 207940.KS Samsung Biologics Co Ltd -1.10% UCB.BR Ucb SA +0.88% BIIB Biogen Inc +1.63%

Company Profile

Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.